TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19858237

Group type: EXPERIMENTAL
Intervention: Bioline
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Phosphorylcholine
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Trillium
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control
Number of subjects: 78
Study: 16884455

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg/day
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Gabapentin 1800 mg/day
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 15541854

Group type: EXPERIMENTAL
Intervention: Manual removal of placenta
Number of subjects: 302

Group type: COMPARATOR
Intervention: Spontaneous removal of placenta
Number of subjects: 302
Study: 11534565

Group type: EXPERIMENTAL
Intervention: Afelimomab (0.3, 1.0, or 3.0 mg/kg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Afelimomab
Number of subjects: 48
Study: 9764987

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid treatment in primary biliary cirrhosis (9 patients underwent second liver biopsy)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Primary biliary cirrhosis and primary sclerosing cholangitis
Number of subjects: 37

Group type: COMPARATOR
Intervention: Controls (7 cases of obstructive jaundice, 10 of hepatitis C virus‐related liver cirrhosis, 14 of chronic hepatitis C, 5 histologically normal liver cases)
Number of subjects: 37
Study: 7826990

Group type: EXPERIMENTAL
Intervention: Series of eight photographs showing weights of portions from the 5th to the 95th centile of portion size
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Single photograph of the average (median) portion size
Number of subjects: 51

Group type: COMPARATOR
Intervention: Average photograph
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Photographs in colour
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Body mass index > or = 30 kg/m2
Number of subjects: 51
Study: 3396267

Group type: EXPERIMENTAL
Intervention: Exercise (n = 13)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (n = 12)
Number of subjects: 25
Study: 29378542

Group type: EXPERIMENTAL
Intervention: Annual mass drug administration (MDA) with praziquantel and albendazole before the peak schistosomiasis transmission season
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Annual MDA after the peak schistosomiasis transmission season
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Two yearly treatments before and after peak schistosomiasis transmission
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Annual MDA before peak schistosomiasis transmission, coupled with chemical snail control using niclosamide
Number of subjects: 200
Study: 27296404

Group type: EXPERIMENTAL
Intervention: Pickled cabbage
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Broccoli
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Cooked onion
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Tomatoes
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Raw carrot
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Cooked carrot
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: More than three portions of cooked vegetables per week
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: High consumption of citrus fruit
Number of subjects: 530
Study: 25908311

Group type: EXPERIMENTAL
Intervention: Supervised personal training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supervised group training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home-based smartphone- and health coach-supported training
Number of subjects: 0
Study: 23063100

Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 1037

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1037
Study: 21646500

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 1012
Study: 19537029

Group type: EXPERIMENTAL
Intervention: Minimal invasive neurosurgery (MG group)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Traditional neurosurgery (TG group)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study: 16705349

Group type: EXPERIMENTAL
Intervention: Aggressive PTK
Number of subjects: 50
Study: 15523309

Group type: EXPERIMENTAL
Intervention: QRS score >=10
Number of subjects: 0

Group type: COMPARATOR
Intervention: QRS score <10
Number of subjects: 0
Study: 11503102

Group type: EXPERIMENTAL
Intervention: Educational intervention in evidence-based ethics
Number of subjects: 64
Study: 9436556

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (300 IU/kg)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (150 IU/kg)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 8355436

Group type: EXPERIMENTAL
Intervention: (2'R)-4'-O-tetrahydropyranyladriamycin (THP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Adriamycin (ADM)
Number of subjects: 21
Study: 2904898

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (group A)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: No antibiotic treatment (group B)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Cerclage (group C)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Cerclage groups (A and B)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Group A (antibiotic treatment)
Number of subjects: 79
Study: 30027499

Group type: EXPERIMENTAL
Intervention: FFR-guided CABG
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angiography-guided CABG
Number of subjects: 0
Study: 28199464

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CCTA)
Number of subjects: 4631

Group type: COMPARATOR
Intervention: Functional testing
Number of subjects: 4631
Study: 26224879

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 23690353

Group type: EXPERIMENTAL
Intervention: CaOH
Number of subjects: 376

Group type: COMPARATOR
Intervention: MTA
Number of subjects: 376
Study: 16648152

Group type: EXPERIMENTAL
Intervention: Desflurane (group D)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sevoflurane (group S)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (D and S)
Number of subjects: 30
Study: 12830021

Group type: EXPERIMENTAL
Intervention: Diet and Exercise Group (DE)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Diet Group (D)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control Group (C)
Number of subjects: 77
Study: 10203118

Group type: EXPERIMENTAL
Intervention: Behavioral intervention implemented between 7:00 p.m. and 6:00 a.m. involving feedback to nursing home staff about noise levels and procedures to abate noise and individualize nighttime incontinence care routines
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 267
Study: 7772420

Group type: EXPERIMENTAL
Intervention: General anaesthesia (NIDDM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anaesthesia (Non-diabetic control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Local anaesthesia (NIDDM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Local anaesthesia (Non-diabetic control)
Number of subjects: 40
Study: 2372525

Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6107932

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (40 mg i.m. 3-times for 6 days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 30075569

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg/vitamin D3 5600 IU (ALN/D5600)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcitriol 0.25 mcg
Number of subjects: 0
Study: 25942016

Group type: EXPERIMENTAL
Intervention: Power capacities (Sargent-jump, broad-jump, medicine-ball-throw)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Zig-zag-Test
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Anthropometric indices
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Agility performance tests (T-Shape-Test, Zig-Zag-Test, T180)
Number of subjects: 92
Study: 26091817

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT) using right unilateral or bitemporal electrode placement and brief or ultrabrief pulse width, administered 3 times per week.
Number of subjects: 74
Study: 23782581

Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.125% plus fentanyl 4 μg ml‐1 (Group F)
Number of subjects: 40

Group type: COMPARATOR
Intervention: levobupivacaine 0.125% (Group L)
Number of subjects: 40
Study: 19028835

Group type: EXPERIMENTAL
Intervention: Thiopental (GABA(A) receptor agonist)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ketamine (NMDA receptor antagonist)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 17996003

Group type: EXPERIMENTAL
Intervention: Venturi system (Starmed) with helmet
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Venturi system (Starmed) with face-mask
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Whisperflow-2 system (Caradyne Ltd) with helmet
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CF800 system (Drägerwerk, AG) with helmet
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CF800 system (Drägerwerk, AG) with face-mask
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mechanical ventilator (Servoventilator 300, Siemens-Elema) with face-mask
Number of subjects: 8
Study: 15941413

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine plus amodiaquine (SP + AQ)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine plus artesunate (SP + AS)
Number of subjects: 438
Study: 12917861

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (20g/d for 5 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10593713

Group type: EXPERIMENTAL
Intervention: Contracted blood sampling protocol (6 samples over 8 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extended blood sampling schedule (15 samples over 48 hours)
Number of subjects: 0
Study: 8606561

Group type: EXPERIMENTAL
Intervention: Quadrantectomy plus axillary dissection and radiotherapy (QUART)
Number of subjects: 1760

Group type: COMPARATOR
Intervention: Halsted mastectomy
Number of subjects: 1760
Study: 1743767

Group type: EXPERIMENTAL
Intervention: Shock-type whole-body vibration with varying amplitude and number of shocks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 17
Study: 7022531

Group type: EXPERIMENTAL
Intervention: Naloxone 1.6 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30967272

Group type: EXPERIMENTAL
Intervention: Experimental group (hands-on training)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Control group (no hands-on training)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Pre-test knowledge assessment
Number of subjects: 298
Study: 28506447

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 25646296

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azilsartan 20 mg
Number of subjects: 0
Study: 23279193

Group type: COMPARATOR
Intervention: Standard medical therapy (gabapentin 300 mg, tramadol 50 mg TDS, methylcobalamin 500 μgm PO)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Extraoral glossopharyngeal nerve block with standard medical therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard medical therapy (gabapentin, tramadol, methylcobalamin)
Number of subjects: 30
Study: 21085001

Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel loading dose
Number of subjects: 84

Group type: COMPARATOR
Intervention: 300 mg clopidogrel loading dose
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups (600 mg and 300 mg clopidogrel)
Number of subjects: 84
Study: 19011955

Group type: EXPERIMENTAL
Intervention: CMAP (Comprehensive Muscular Activity Profile)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Therapists' ratings
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CMAP combined with therapists' ratings
Number of subjects: 80
Study: 17579942

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg for 2 weeks
Number of subjects: 368

Group type: COMPARATOR
Intervention: Endoscopy
Number of subjects: 368

Group type: COMPARATOR
Intervention: PPI strategy
Number of subjects: 368
Study: 15385381

Group type: EXPERIMENTAL
Intervention: Single-injection (Group 1)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Dual-injection (Group 2)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Triple-injection (Group 3)
Number of subjects: 75
Study: 11306155

Group type: EXPERIMENTAL
Intervention: Three different antiretroviral strategies
Number of subjects: 0
Study: 9642898

Group type: COMPARATOR
Intervention: Brief advice
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Motivational interview
Number of subjects: 40
Study: 8124794

Group type: EXPERIMENTAL
Intervention: RV‐‐>CAN (unipolar defibrillation system)
Number of subjects: 15

Group type: COMPARATOR
Intervention: RV‐‐>SVC + CAN (three‐electrode dual pathway system)
Number of subjects: 15
Study: 2570100

Group type: EXPERIMENTAL
Intervention: Passive method (posters and pamphlets) in group B
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Active method (in-service lectures) in group C
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Active method (in-service lectures) in group C after 6 months
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Passive method (posters and pamphlets) in group B after 6 months
Number of subjects: 9

Group type: COMPARATOR
Intervention: Simple announcement in group A (control)
Number of subjects: 9
Study: 786302

Group type: EXPERIMENTAL
Intervention: Carbocromen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Papaverine
Number of subjects: 100
Study: 31712614

Group type: EXPERIMENTAL
Intervention: Multispecies probiotic
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 30540659

Group type: EXPERIMENTAL
Intervention: Anal acoustic reflectometry
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fast rate anal acoustic reflectometry (5 cm H2O/1 s)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Normal rate anal acoustic reflectometry (5 cm H2O/3 s)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Manometry
Number of subjects: 80
Study: 28599628

Group type: EXPERIMENTAL
Intervention: FOLFOX plus bevacizumab followed by FOLFIRI plus bevacizumab after disease progression
Number of subjects: 0

Group type: COMPARATOR
Intervention: FOLFOXIRI plus bevacizumab followed by re-introduction of the same regimen after disease progression
Number of subjects: 0
Study: 25716658

Group type: EXPERIMENTAL
Intervention: NexGard®
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bravecto™
Number of subjects: 24

Group type: COMPARATOR
Intervention: NexGard® vs Bravecto™
Number of subjects: 24
Study: 23747935

Group type: EXPERIMENTAL
Intervention: Hippotherapy exercise program (two 30‐min sessions per week for 14 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 19
Study: 21300923

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 350

Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 350
Study: 19322527

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17121210

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Insulin isophane
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 3000
Study: 14692558

Group type: EXPERIMENTAL
Intervention: Autohaler
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Turbuhaler
Number of subjects: 200
Study: 11572420

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination protocol with follow-up contacts (5 postcards, 10 phone calls, 3 home visits)
Number of subjects: 85
Study: 9039333

Group type: EXPERIMENTAL
Intervention: Growth hormone (2 IU/m2 per day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 1406395

Group type: EXPERIMENTAL
Intervention: Combination therapy (colestipol 5 g or 10 g + simvastatin 20 mg/night then 40 mg/night)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Simvastatin monotherapy
Number of subjects: 61
Study: 3966330

Group type: EXPERIMENTAL
Intervention: Lorcainide
Number of subjects: 100

Group type: COMPARATOR
Intervention: Procainamide
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Other antiarrhythmic drug regimens
Number of subjects: 100
Study: 30172724

Group type: EXPERIMENTAL
Intervention: Active tDCS (2.5 mA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS (34 μA)
Number of subjects: 0
Study: 27332627

Group type: EXPERIMENTAL
Intervention: Transdermal Rivastigmine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed model for C8h, C12h, and C18h
Number of subjects: 0
Study: 25180379

Group type: EXPERIMENTAL
Intervention: Cranberry capsules
Number of subjects: 928

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 928
Study: 23033347

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 5599

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 5599
Study: 20620411

Group type: EXPERIMENTAL
Intervention: 12 Gy prophylactic radiotherapy before bicalutamide
Number of subjects: 125

Group type: COMPARATOR
Intervention: Bicalutamide only (nonprophylactic)
Number of subjects: 125
Study: 18689589

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (AT) for SDB in obese children
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (AT) for SDB in nonobese children
Number of subjects: 70
Study: 16044793

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12004993

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (88 microg [2 puffs of 44 microg] twice daily)
Number of subjects: 522

Group type: COMPARATOR
Intervention: Montelukast (10 mg/d)
Number of subjects: 522
Study: 10464834

Group type: EXPERIMENTAL
Intervention: Inhaled ceftazidime and tobramycin (group A)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Symptomatic treatment (group B)
Number of subjects: 15
Study: 7853037

Group type: EXPERIMENTAL
Intervention: Analytic meta-analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exploratory meta-analysis
Number of subjects: 0
Study: 2240724

Group type: EXPERIMENTAL
Intervention: Lidocaine (1 mg/kg IV bolus, followed by 2 mg/min IV drip, with a second bolus of 0.5 mg/kg after 10 minutes)
Number of subjects: 1427

Group type: COMPARATOR
Intervention: Control (no lidocaine treatment)
Number of subjects: 1427

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 1427

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1427
Study: 350499

Group type: EXPERIMENTAL
Intervention: 100 mg indomethacin plus 10 mg diazepam
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 200 mg sulindac
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 200 mg sulindac plus 10 mg diazepam
Number of subjects: 18
Study: 6752070

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate nasal spray (400 micrograms daily)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 70
Study: 29993815

Group type: EXPERIMENTAL
Intervention: New method for predicting sigma‐54 promoters using motif finding and machine learning strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New method for predicting sigma‐54 promoters
Number of subjects: 0
Study: 29225003

Group type: EXPERIMENTAL
Intervention: RVM (Respiratory Volume Monitor)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control (no access to RVM data)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: RVM rated as 'not useful'
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: RVM rated as 'somewhat useful'
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: RVM rated as 'very useful'
Number of subjects: 73
Study: 27444687

Group type: EXPERIMENTAL
Intervention: Targeted case-finding group
Number of subjects: 74818

Group type: EXPERIMENTAL
Intervention: Active case-finding group
Number of subjects: 74818

Group type: EXPERIMENTAL
Intervention: Opportunistic case-finding group
Number of subjects: 74818

Group type: COMPARATOR
Intervention: Routine care group
Number of subjects: 74818

Group type: COMPARATOR
Intervention: Active case-finding vs Opportunistic case-finding
Number of subjects: 74818

Group type: COMPARATOR
Intervention: Cost-effectiveness of Active vs Opportunistic case-finding
Number of subjects: 74818
Study: 25265284

Group type: COMPARATOR
Intervention: Intranasal insulin (40 IU)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Oral cortisol (30 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Both intranasal insulin and oral cortisol
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 22464310

Group type: EXPERIMENTAL
Intervention: Intradetrusor onabotulinumtoxinA (50 U, 100 U, 150 U, 200 U, or 300 U)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Intradetrusor onabotulinumtoxinA (doses ≥100 U)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study: 21061865

Group type: EXPERIMENTAL
Intervention: Stages‐of‐change motivational interviewing (SOCMI)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Standard cognitive behavioral therapy gender reeducation (CBTGR)
Number of subjects: 528
Study: 17647298

Group type: EXPERIMENTAL
Intervention: Citalopram (20‐60 mg/day) for 6 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sertraline (50‐150 mg/day) for 6 weeks
Number of subjects: 100